Additional Study Information: Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT. The aim of the FAST Registry is to record the treatment your doctor prescribes, your ongoing care, and the outcome of your pregnancy up to one month after birth.